The archive · Health & Care · Product decision · 2012–2025
Synchron's endovascular BCI bet: 10 implants, thought-controlled iPad, $200M Series D
Synchron bets a stent-like electrode threaded through a vein beats open-skull BCIs; ten patients are implanted and a $200M round targets commercial launch.
Synchron
What the business is
Synchron makes Stentrode, an endovascular brain-computer interface threaded through the jugular vein to the motor cortex, letting people with paralysis control phones, tablets and computers by thought.
Starting capital：$200M Series D announced November 2025, led by Double Point Ventures, bringing total funding to US$345M at about a US$1B valuation; Australia's National Reconstruction Fund contributed A$54M (Forbes Australia).
How it started
The BCI was developed by neurologist Thomas Oxley and biomedical engineer Nicholas Opie starting in 2011, spun out of the University of Melbourne in 2012, and moved its headquarters to Brooklyn in 2016 (Forbes Australia). First human implants followed by 2019 — about five years ahead of Neuralink's.
What happened
Synchron has implanted Stentrode in ten patients with paralysis across US and Australian trials under an FDA investigational device exemption (MacRumors; Healio). In 2024 COMMAND participant Mark first controlled an Apple Vision Pro by thought; in August 2025 Synchron showed him driving an iPad natively through Apple's BCI-HID protocol — the first public thought-controlled iPad (MacRumors). The November 2025 Series D, including A$54M from Australia's National Reconstruction Fund, funds pivotal trials, manufacturing scale-up, and a next-generation whole-brain interface promised for late 2026 (Forbes Australia; Healio).
How it ended up
Still live and pre-commercial: Stentrode is in FDA IDE studies with ten implants, and the Series D positions Synchron to run pivotal trials and prepare a commercial launch of its first-generation platform (Healio).
Background
Synchron was spun out of the University of Melbourne in 2012 to prove a counter-intuitive bet: a brain-computer interface does not need to open the skull. Its Stentrode — a self-expanding electrode mesh threaded through the jugular vein to sit in a blood vessel over the motor cortex — records motor-intent signals so people with paralysis can control digital devices by thought.
The bet showed early results. Human implants began by 2019, and by August 2025 Stentrode had been placed in ten patients with paralysis in US and Australian trials under an FDA investigational device exemption. In 2024 a COMMAND participant named Mark controlled an Apple Vision Pro; in August 2025 he demonstrated the first public thought-controlled iPad using Apple's BCI-HID protocol, with no touch, voice or eye tracking.
In November 2025 Synchron raised a US$200M Series D led by Double Point Ventures, bringing total funding to US$345M at about a US$1B valuation. Australia's National Reconstruction Fund put in A$54M on condition Synchron rebuild an Asia-Pacific base in Melbourne. The money funds pivotal trials, manufacturing scale-up and a next-generation, catheter-delivered whole-brain interface promised for late 2026.
Synchron frames Stentrode for people with severe paralysis — such as ALS, spinal cord injury or stroke — who retain motor intent, aiming to restore digital independence without invasive surgery. Commercial launch still depends on pivotal-trial results and regulatory approval.
What has to be true
- Milestone is dated and concrete: ten implants under FDA IDE and the first public thought-controlled iPad demo in August 2025.
- The bet is crisp: endovascular access, not open-brain surgery, is the route to a scalable BCI — a direct contrast with Neuralink.
- Verifiable coverage: Forbes Australia, Healio and MacRumors report the same funding and clinical facts.
- Scale is real but honest: US$345M raised and about a US$1B valuation against a better-funded rival.
What can be applied
Pick the least invasive route to the outcome: Synchron's catheter implant reached humans years before Neuralink's surgical chip, on a fraction of the funding and a safer regulatory story.
Aftermath
As of November 2025, Synchron has ten Stentrode implants across US and Australian trials and is using its $200M Series D to run pivotal trials, scale manufacturing, build engineering teams in San Diego and AI and clinical teams in New York, and rebuild a Melbourne presence tied to the NRF investment. A next-generation, catheter-delivered whole-brain interface is promised for late 2026. No commercial product has launched yet; regulatory approval and pivotal-trial data remain the gate.
Sources
- Synchron raises $308m to leapfrog Neuralink – with $54m from Australian taxpayer
- Synchron raises $200M to advance brain-computer interface tech for paralysis
- Watch Brain-Controlled iPad in Action for the First Time
- Synchron raises US$200 million in Series D financing to advance BCI technology
spotted an error? The archive wants to know.
Your turn
You just read one. Describe what you are building, and see who is betting on the same thing.
Free account · 3 free questions · no card